Compare UNB & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | UNB | RFL |
|---|---|---|
| Founded | 1891 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Real Estate |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.6M | 133.1M |
| IPO Year | 1999 | 2017 |
| Metric | UNB | RFL |
|---|---|---|
| Price | $23.35 | $1.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.7K | ★ 130.9K |
| Earning Date | 04-15-2026 | 06-10-2026 |
| Dividend Yield | ★ 5.76% | N/A |
| EPS Growth | 25.52 | ★ 28.28 |
| EPS | ★ 1.25 | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.80 | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $20.65 | $1.12 |
| 52 Week High | $26.41 | $3.96 |
| Indicator | UNB | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 41.58 | 39.40 |
| Support Level | $22.95 | $1.86 |
| Resistance Level | $24.22 | $2.16 |
| Average True Range (ATR) | 0.27 | 0.18 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 7.81 | 6.15 |
Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The Company has one definable business segment, Union Bank, which provides full retail, commercial, municipal banking, and wealth management and trust services throughout its 18 branch banking locations, three loan centers, and several ATMs covering northern Vermont and northern New Hampshire. In addition, it also offers fiduciary and asset management services through its Asset Management Group.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.